These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8035933)

  • 1. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
    Ruottinen HM; Rinne JO; Ruotsalainen UH; Bergman JR; Oikonen VJ; Haaparanta MT; Solin OH; Laihinen AO; Rinne UK
    J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):91-106. PubMed ID: 9620057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
    Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
    Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
    J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
    Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
    Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
    Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
    Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
    Smith LA; Gordin A; Jenner P; Marsden CD
    Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
    Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
    Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
    Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.